SPECIAL NOTICE
A -- Medical CBRN Defense Consortium Other Transaction Agreement (OTA)
- Notice Date
- 10/24/2018
- Notice Type
- Special Notice
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of the Army, Army Contracting Command, ACC - NJ (W15QKN), BUILDING 10 PHIPPS RD, PICATINNY ARSENAL, New Jersey, 07806-5000, United States
- ZIP Code
- 07806-5000
- Solicitation Number
- W15QKN16Z04B5
- Archive Date
- 10/24/2019
- Point of Contact
- Emily A. Pellegrino,
- E-Mail Address
-
emily.a.pellegrino2.civ@mail.mil
(emily.a.pellegrino2.civ@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- This is not a notice for a solicitation. This is not a Request for Proposal or Request for Whitepapers. This is a Special Notice to advise interested parties of opportunities under a Section 815 Other Transaction Agreement (OTA) for Prototype Projects under 10 U.S.C. 2371b. The Army Contracting Command - New Jersey (ACC-NJ), on behalf of the Joint Program Executive Officer for Chemical and Biological Defense (JPEO-CBD) has established an Other Transaction Agreement (OTA) with the Medical CBRN Defense Consortium (MCDC) for use by agencies that have a need to prototype new technologies related to Medical Countermeasure Systems. The prototyping requirements include any technologies that advance development efforts to support the Department of Defense's medical, pharmaceutical, and diagnostic requirements as related to enhancing the mission effectiveness of military personnel. These technologies include: accelerating the development of mission critical technologies in the areas of concern from applied research into advanced development; delivering therapeutic medical countermeasure prototypes targeting viral, bacterial and biological toxin targets of interest to the DoD; delivering enabling technologies that will support the development of regulatory review of medical countermeasure prototypes; developing prototype candidates for the prophylaxis, treatment and diagnosis of radiological and nuclear threats including acute radiation syndrome; developing soldier-carried auto-injector delivery devices for single drug administration; developing vaccine-manufacturing platforms that offer early stage manufacturing flexibility and diversity; pharmaceutical development addressing the FDA Animal Rule, as appropriate; supporting a family of systems diagnostic approach that increases the speed, accuracy, and confidence of agent identification and disease diagnosis; supporting the Critical Reagents Program, the principal DoD resource of standardized biological reference materials, reagents, and assays, as necessary; addressing DoD Advanced Development and Manufacturing capabilities; and pursuing collaborative research. The Government is seeking prototype projects designed to enhance mission effectiveness and to develop and mature technologies in the field of medical CBRN defense. Possible requirements would encompass activities that span all phases of acquisition as described in the DODI 5000.02. These capability areas support the DoD strategy for medical CBRN defense in the following technical areas: •Prevention - Prophylaxis, pre-treatment, and post-exposure prophylaxis •Diagnosis - Systems and devices to identify CBRN agents and assist in making medical decisions •Treatment - Therapeutics for post-exposure and post-symptomatic The OTA consortium model allows for increased, streamlined collaboration between the Government and Consortium membership. The OTA consortium model is a unique acquisition tool that allows for more open communication and emphasizes engaging a diversified range of membership - from academia to industry suppliers. Per 10 U.S.C. 2371b, the process shall include significant non-traditional participation. The MCDC Consortium model operates via a single set of terms and conditions through the single-point contracting agent for the Consortium, or Consortium Management Firm (CMF). As a result, the OTA process decreases acquisition time and cost, enabling rapid technology and prototype solutions. Membership in the MCDC Consortium allows for networking with stakeholders including Government, Industry, and Academia. Please note that those interested in potential Prototype OTA for these technical areas should be aware that anticipated solicitations will include the following statement relative to the potential for follow-on production: "In accordance with 10.U.S.C. 2371b(f), and upon a determination that the prototype project for this transaction has been successfully completed, this competitively awarded prototype OTA may result in the award of a follow-on production contract or transaction without the use of competitive procedures." Interested parties can be directed to https://www.medcbrn.org to obtain information on membership, as well as pending and projected awards. Companies that are part of the Academia, US Defense Industrial base as well as new and emerging non-traditional defense contractors and are encourage to join the MCDC and participate in Federally-funded R&D projects. Any questions should be addressed to the CMF, ATI, at MCDC@ati.org.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/43585362377bfa9b787b398ff20f928e)
- Record
- SN05133229-W 20181026/181024230535-43585362377bfa9b787b398ff20f928e (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |